Compile Data Set for Download or QSAR
maximum 50k data
Found 42 Enz. Inhib. hit(s) with all data for entry = 258
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261498(2-(4-(bromomethyl)phenyl)-1,1,1,3,3,3-hexafluoropr...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261506(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261498(2-(4-(bromomethyl)phenyl)-1,1,1,3,3,3-hexafluoropr...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261499(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261499(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261499(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261500(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261500(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261500(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261501(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261501(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261502(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261502(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261503(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261503(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261504(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261504(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261504(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261505(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261505(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261505(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261506(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261506(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261506(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261507(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261507(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261507(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261508(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261508(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261508(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-17A(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261509(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261509(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-22 receptor subunit alpha-2(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261509(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261498(2-(4-(bromomethyl)phenyl)-1,1,1,3,3,3-hexafluoropr...)
Affinity DataIC50: <1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261499(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261500(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261501(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261502(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261503(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261504(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: <1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261505(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)...)
Affinity DataIC50: >1.00E+4nMAssay Description:Compound binding to the human RORγ LBD was assessed using the Human RORγ Assay System (INDIGO Biosciences Inc.) as per manufacturer's i...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetInterleukin-17F(Homo sapiens (Human))
Innov17

US Patent
LigandPNGBDBM261498(2-(4-(bromomethyl)phenyl)-1,1,1,3,3,3-hexafluoropr...)
Affinity DataIC50: <1.00E+4nMAssay Description:Human CD4+ T cells were differentiated to TH17 cells as described in the presence or absence of various concentrations of compounds in a final concen...More data for this Ligand-Target Pair
In DepthDetails US Patent